Sanofi

Joslin Diabetes Center, Inc.

Matthias Lohmann

Heiner Glombik

Kurt Ritter

Lothar Schwink

Christian Buning

Nis Halland

Christoph Pöverlein

Dieter Kadereit

Matthias Gossel

Rohit N Kulkarni

Abdelfattah El Ouaamari

Daniel Margerie

Jean Claude Guillemot

Denis Loyaux

The present disclosure relates to azetidine compounds. The azetidine compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The present disclosure furthermore relates to the use of azetidine compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

Azetidine compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders

The present invention relates to isoindolinone compounds. The isoindolinone compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of isoindolinone compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

Isoindolinone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders

The present invention relates to indanone compounds. The indanone compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of indanone compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

Substituted indanone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders

Compositions and methods of use are provided for improving &#x3b2; cell function and promoting pancreatic &#x3b2; cell proliferation in vitro, in vivo and ex vivo. The active agents of the pending invention comprise Serpin family peptides (e.g., SerpinB1), functional and structural analogs of Serpin family peptides and nucleic acids encoding Serpin family peptides, as well as active fragments thereof.

Serpins: methods of therapeutic &#x3b2;-cell regeneration and function

The present invention relates to substituted fused heterocyclic compounds. The substituted fused heterocyclic compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of substituted fused heterocyclic compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

Substituted fused heterocycles as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders

Growing community of inventors

Frankfurt am Main, Germany

Matthias Lohmann